uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group
Astellas, 1 Astellas Way, Northbrook, IL 60062 USA..
Merck & Co Inc, 351 N Sumneytown Pike, N Wales, PA 19454 USA..
Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA..
Eli Lilly & Co Chorus, Lilly Corp Ctr, Indianapolis, IN 46285 USA..
Show others and affiliations
2016 (English)In: Journal of Pharmacokinetics and Pharmacodynamics, ISSN 1567-567X, E-ISSN 1573-8744, Vol. 43, no 2, 123-135 p.Article in journal, Editorial material (Other academic) PublishedText
Abstract [en]

The purpose of this work was to present a consolidated set of guidelines for the analysis of uncontrolled concomitant medications (ConMed) as a covariate and potential perpetrator in population pharmacokinetic (PopPK) analyses. This white paper is the result of an industry-academia-regulatory collaboration. It is the recommendation of the working group that greater focus be given to the analysis of uncontrolled ConMeds as part of a PopPK analysis of Phase 2/3 data to ensure that the resulting outcome in the PopPK analysis can be viewed as reliable. Other recommendations include: (1) collection of start and stop date and clock time, as well as dose and frequency, in Case Report Forms regarding ConMed administration schedule; (2) prespecification of goals and the methods of analysis, (3) consideration of alternate models, other than the binary covariate model, that might more fully characterize the interaction between perpetrator and victim drug, (4) analysts should consider whether the sample size, not the percent of subjects taking a ConMed, is sufficient to detect a ConMed effect if one is present and to consider the correlation with other covariates when the analysis is conducted, (5) grouping of ConMeds should be based on mechanism (e.g., PGP-inhibitor) and not drug class (e.g., beta-blocker), and (6) when reporting the results in a publication, all details related to the ConMed analysis should be presented allowing the reader to understand the methods and be able to appropriately interpret the results.

Place, publisher, year, edition, pages
2016. Vol. 43, no 2, 123-135 p.
Keyword [en]
Population pharmacokinetics, Covariate modeling, Drug interactions, Concomitant, Medications
National Category
Pharmacology and Toxicology
URN: urn:nbn:se:uu:diva-299186DOI: 10.1007/s10928-016-9464-2ISI: 000374704100001PubMedID: 26837775OAI: oai:DiVA.org:uu-299186DiVA: diva2:949048
Available from: 2016-07-15 Created: 2016-07-15 Last updated: 2016-07-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Karlsson, Mats O.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Journal of Pharmacokinetics and Pharmacodynamics
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 74 hits
ReferencesLink to record
Permanent link

Direct link